Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1

Stopped Based on the promising interim results of study part 1, it was decided to further accelerate the development of the 2nd generation DNA plasmid immunotherapy. Therefore enrolment of patients was completed after study part 1

Conditions

• Melanoma Stage IV
• Melanoma Stage III

Interventions

• DRUG: EVX-02A
• DRUG: EVX-02B
• DRUG: EVX-02A OR EVX-02B

Sponsor

Evaxion Biotech A/S

Collaborators

• [object Object]